Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Share :
Published: 9 Jun 2022
Views: 152
Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Dr Timothy Whelan presents LUMINA study findings, which showed based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely.

He discusses the methodology and results of the study.

The LUMINA study enrolled participants whose biomarker screening results showed that 13.25% or less of the tumour cells had the protein marker, Ki67, which is associated with cancer cell proliferation and is consistent with the luminal A breast cancer subtype.

The patients in the study will continue to be followed for up to 10 years for effects on long term recurrence and survival. 

Watch our interview with Dr Whelan here

Watch Dr Speers comment on the study here

Watch Dr Bishal Gyawali comment on the study here

Read our news story about the study here